Abstract 2169
Background
Cancer patients and their caregivers are expected to take joint responsibility with regard to reporting symptoms and seeking medical assistance e.g. by calling oncology emergency telephones or other helplines during their cancer trajectory. This responsibility may pose additional burdens on patients and caregivers when they are at home with symptoms that can be potential life threatening. Furthermore, in this vulnerable situation, the ability to handle the responsibility is compromised, which may influence safeguarding fundamentals of care needs. Therefore, the objective of this study is to explore the meaning of responsibility as it appeared in patients or caregivers calls to an oncology emergency telephone.
Methods
Qualitative description and qualitative content analysis guided a secondary analysis and interpretation of data from interviews with 12 participants calling an oncology emergency telephone.
Results
The analysis revealed two main themes. 1). To act responsibly as patient or caregivers was elaborated by: ‘Being watchful and alert’, ‘Reporting the symptoms’, and ‘Cross checking’. 2). To deal with the burden of responsibility was elaborated by the sub-themes: ‘Feeling safe in dealing with the burden of responsibility’, and ‘Being relieved from the burden of responsibility’.
Conclusions
Conclusion: The study provided essential knowledge on how patients and caregivers handle responsibility in their everyday living with a cancer disease, treated on an outpatient basis. The meaning of responsibility appeared in the informants’ capacity to act where they displayed responsibility to observe, assess and report symptoms and control prescribed treatment as well as to share or hand over the responsibility to the healthcare providers. Easing the burden of responsibility requires a person-centered approach that integrates physical, psychosocial and relational needs and bridge a potential imbalance between healthcare providers’ expectations and the patients’ or caregivers knowledge and capacity to act. For this to succeed, establishing a caring relationship between HCPs, patients and caregivers is essential.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Birgith Pedersen.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract